Peptide EncyclopediaA clinical monograph on tirzepatide — the dual GIP/GLP-1 co-agonist sold as Mounjaro and Zepbound. Grade-A RCT evidence for diabetes, obesity and sleep apnea, with a boxed warning and a tightening 2026 compounding landscape.
Peptide Encyclopedia13 MIN READ
Peptide EncyclopediaA clinical monograph on semaglutide — the long-acting GLP-1 receptor agonist behind Ozempic, Wegovy and Rybelsus. Grade-A human RCT evidence across diabetes, obesity, cardiovascular, kidney and liver disease.
Peptide Encyclopedia12 MIN READ
Peptide EncyclopediaA clinical monograph on exenatide — the first-in-class GLP-1 receptor agonist (synthetic exendin-4) — with a focus on its Grade A pediatric type 2 diabetes evidence, mechanism, dosing from the literature, safety, and 2026 regulatory status.
Peptide Encyclopedia11 MIN READ